GlycoMimetics Reaches New 12-Month Low at $6.12 (GLYC)
GlycoMimetics (NASDAQ:GLYC) reached a new 52-week low during mid-day trading on Friday , American Banking News.com reports. The company traded as low as $6.12 and last traded at $6.23, with a volume of 50,040 shares changing hands. The stock had previously closed at $6.45.
A number of analysts have recently weighed in on GLYC shares. Analysts at Stifel Nicolaus raised their price target on shares of GlycoMimetics from $14.00 to $16.00 in a research note on Tuesday, April 15th. They now have a “buy” rating on the stock. Analysts at Jefferies Group raised their price target on shares of GlycoMimetics from $13.00 to $20.00 in a research note on Tuesday, April 1st.
The stock has a 50-day moving average of $8.51 and a 200-day moving average of $11.33. The company’s market cap is $115.0 million.
GlycoMimetics (NASDAQ:GLYC) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.30) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.29) by $0.01. On average, analysts predict that GlycoMimetics will post $0.09 earnings per share for the current fiscal year.
In other GlycoMimetics news, Director Michael A. Henos bought 11,000 shares of GlycoMimetics stock in a transaction that occurred on Friday, June 13th. The shares were purchased at an average cost of $6.39 per share, for a total transaction of $70,290.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
GlycoMimetics, Inc (NASDAQ:GLYC) is a clinical-stage biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.